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Introduction
Bile acids are the end products of cholesterol catabolism. The five major bile acids in humans are chenodeoxycholate (CDCA), deoxycholate (DCA), cholate (CA), ursodeoxycholate (UDCA) and lithocholate (LCA) (1) . In addition to their critical roles in lipid and vitamin absorption, bile acids are ligands for the nuclear receptor FXR and regulate expression of genes whose products are critically important for bile acid and cholesterol homeostasis (2) (3) (4) . Agonist bound-FXR activates expression of the bile salt export pump (BSEP) (5, 6) , intestinal bile acid binding protein (7) , phospholipid transfer protein (8) , dehydroepiandrosterone sulfotransferase (9) , apolipoprotein C-II (10) , apolipoprotein E (11) and kininogen (12). FXR represses expression of cholesterol 7α-hydroxylase (Cyp7a) (11, (13) (14) (15) , sterol 12 α-hydroxylase (16), the Na + /taurocholate co-transporting polypeptide (17) and apolipoprotein A-I (18) .
A few functional distinct classes of FXR ligands have been identified. We have previously shown that LCA is an FXR antagonist and guggulsterones are selective bile acid receptor modulators (SBARMs) (6, 19) . GW4064 is a synthetic FXR agonist (20) . Bile acids, such as CDCA, DCA and CA, have been previously shown to be FXR agonists that regulate expression of FXR targets (2) (3) (4) . In this study, we systematically characterized the FXR agonist activities of these bile acids using a series of cell-free and cell-based assays including coactivator recruitment, GST pull-down, FXR transactivation and quantitative real-time PCR for examining
Materials and Methods
Reagents. FXR transactivation. HepG2 cells were transfected in 96-well plates using the FuGENE6 transfection reagent as described previously (22). FXR transactivation assay using pGL3-enhancer-hBSEP-Promoter-Luc construct was performed as described previously (19) .
Treatment of transfected cells with various FXR ligands, assays for luciferase and β-
galactosidase activities were also performed as previously described (22 The binding affinity of the same panel of bile acids was determined by a FXR SPA binding assay. As shown in Table I , LCA had the highest binding affinity on FXR with an IC50 of 3 µM. CDCA bound to FXR with an IC50 of 17 µM, while DCA and UDCA had an IC50 of 131 µM and 185 µM respectively. CA was the weakest binder among the five bile acids with an IC50 of 586 µM. The conjugated CA and CDCA had a similar IC50 to the cognate unconjugated bile acid. These data suggest that lack of the agonist activity for DCA and UDCA in the FXR coactivator association assay was not due to lack of the binding of FXR since CA, a much weaker binder, was able to activate FXR.
CDCA, but not other bile acids, promotes the interaction of FXR and SRC-1 in a GST pull-down
assay. To confirm the results that unique bile acids can result in different levels of recruitment of SRC-1 by FXR, these bile acids were also evaluated in a GST pull-down assay. Similar to the FXR coactivator association assay, the GST pull-down assay measures interaction of SRC-1 with the ligand bound-FXR in a cell-free environment. Consistent with the results in FXR coactivator association assay, CDCA promoted the interaction of SRC-1 with FXR in a dose-dependent manner with an EC50 approximately 1-2 µM and a saturation concentration of between 8-16 µM determined by densitometry ( Fig. 2A) . However, DCA, CA, UDCA or LCA at 32 µM were inactive in this assay (Fig. 2B ). GW4064, a synthetic FXR agonist, also promoted the interaction of SRC-1 with FXR. At 50 nM, GW4064 showed a comparable level of activity to that of 32 µM CDCA (Fig. 2B ). These results demonstrate again that distinct FXR ligands can differentially promote FXR-coactivator interaction.
Bile acids in FXR transactivation with the BSEP promoter. BSEP, the major bile acid transporter in the liver, is transcriptionally activated by FXR through an FXRE in the BSEP promoter (5).
The activity of each bile acid was also compared in FXR transactivation assays using a BSEP promoter-driven luciferase construct. CDCA increased luciferase activity in a dose-dependent fashion with a maximum induction of 25-to 30-fold (Fig. 3A) . In the same experiment, DCA, CA and UDCA maximally increased luciferase activity by 20-, 15-and 8-fold respectively, approximately 80%, 60% and 30% respectively of the CDCA activity (Fig. 3B-D) . DCA, CA
and UDCA also had a higher EC50 than that of CDCA (Fig. 3A-D) . Thus, DCA, CA and UDCA act as partial agonists of FXR when compared to CDCA.
Bile acids in expression of endogenous BSEP. It was previously reported that FXR agonists strongly induced BSEP expression in HepG2 cells (6) . In this study, these bile acids were also evaluated for their ability to regulate BSEP expression to quantify their agonist activities on FXR relative to CDCA, which we operationally define as a full agonist. HepG2 cells were treated with each of CDCA, CA, DCA or UDCA and BSEP mRNA was quantified by real-time PCR (TaqMan). Consistent with our previous report (6), CDCA strongly induced BSEP expression up to 750-fold with an EC50 of 25 to 50 µM (Fig. 4A) , while DCA showed a partial induction up to 250-fold with an EC50 of 50-75 µM (Fig. 4B) . CA treatment resulted in a much lower induction up to 75-fold at 600 µM (Fig. 4C) , and UDCA had the weakest induction of only 15-fold (Fig.   4D ). These data indicate that various bile acids display different abilities in induction of BSEP expression.
Bile acids in repression of Cyp7a expression. It has been well established that FXR agonists repress Cyp7a mRNA. This repression is believed to be mediated primarily by the orphan nuclear receptors SHP and CPF (14, 15) . We thus evaluated the same panel of bile acids for repression of Cyp7a mRNA to further assess relative activities on another FXR target. Consistent with the result in BSEP expression, again, CDCA was the most potent bile acid in decreasing Cyp7a expression with an EC50 around 10 µM (Fig. 5A) . Interestingly, DCA, CA and UDCA also effectively repressed Cyp7a expression although with higher EC50 values (Fig. 5B-D) . In particular, UDCA, which was a very weak FXR agonist in other assays, decreased Cyp7a mRNA by 80% at 400 µM (Fig. 5D) . (Fig. 6A) . In addition to CDCA, the other three bile acids, DCA, CA and UDCA, also significantly increased FXR protein levels (Fig. 6B) . Again, CDCA was the most potent inducer of FXR protein expression (Fig. 6B) . Similar to the results in down-regulation of Cyp7a mRNA, both DCA and UDCA showed a significant induction of FXR protein expression (Fig. 6B) . The synthetic FXR agonist GW4064 also effectively increased FXR protein (Fig. 6C ). These data indicate that both endogenous and synthetic FXR agonists can effectively increase FXR protein expression and that the extent of induction was similar for full, high-partial and low-partial agonists of FXR. The efficient induction of FXR by various FXR agonists suggests that this auto-regulatory loop may play an important role in FXR-mediated gene regulation.
Discussion
We previously demonstrated that LCA was an FXR antagonist that decreased the FXR agonist-induced BSEP transcription (6) . In this study, we systematically characterized the other four bile acids in FXR function using a series of cell-free and cell-based assays. We showed here that CDCA was the most potent FXR agonist in cell-free assays and effectively regulated expression of BSEP and Cyp7a and also strongly increased FXR protein expression in HepG2 cells. Interestingly, we observed that DCA, CA and UDCA were partial FXR agonists in FXR
transactivation assays yet regulated FXR targets in a gene-selective fashion. The three bile acids partially increased BSEP expression but they repressed Cyp7a mRNA and increased FXR protein expression with nearly equal effects as CDCA.
Bile salt export pump (BSEP) is a major hepatic bile acid transporter whose deficiency in humans results in progressive familial intrahepatic cholestasis, a severe liver disease that impairs bile flow and causes irreversible liver damage (24) . BSEP is a direct FXR target and FXR agonists strongly induce BSEP mRNA in both primary human hepatocytes and HepG2 cells (5, 6) . The efficacy and potency of bile acids in FXR transactivation assays correlate well with that in BSEP expression (Figs. 3 and 4) .
Cholesterol 7α-hydroxylase (Cyp7a) catalyzes the first and rate-limiting step in the conversion of cholesterol to bile acids. It is well established that bile acids feedback inhibit Cyp7a production. Three pathways have been postulated to be responsible for this feedback repression. The first pathway, probably the predominant one, involves FXR up-regulation of SHP that in turn suppresses the activity of CPF, a critical positive regulator of Cyp7a (13) (14) (15) 25, 26) . The importance of this pathway is indicated by the fact that Cyp7a expression was elevated in SHP KO mice (27, 28) . However, the bile acid-mediated Cyp7a repression was not completely abolished in SHP KO mice (27, 28) 32. Takeyama, K., Kojima, R., Ohashi, R., Sato, T., Mano, H., Masushige, S., and Kato, S.
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